阿法骨化醇
医学
骨矿物
骨质疏松症
内科学
内分泌学
泌尿科
作者
Toshio Matsumoto,Kazuhiko Yamamoto,Tsutomu Takeuchi,Yoshiya Tanaka,Sakae Tanaka,Tetsuo Nakano,Masako Ito,Tatsushi Tomomitsu,Akihiro Hirakawa,Satoshi Soen
标识
DOI:10.1007/s00774-020-01091-4
摘要
Eldecalcitol increases bone mineral density (BMD) and reduces vertebral fracture in patients with primary osteoporosis. However, the effect of eldecalcitol on BMD and fracture in glucocorticoid-induced osteoporosis (GIO) patients is unknown. This study was undertaken to compare the effect of eldecalcitol on BMD and fracture with that of alfacalcidol in GIO patients. A randomized, open-label, parallel group study was conducted to identify the effectiveness and safety of monotherapy with 0.75 μg eldecalcitol compared with 1.0 μg alfacalcidol in GIO patients. Lumbar spine BMD increased with eldecalcitol, but decreased with alfacalcidol at 12 and 24 months (between group difference 1.29%, p 70% of the young adult mean, and with ≤ 3 months of previous glucocorticoid treatment. No significant difference in the incidence of vertebral fracture was found, and the incidence of adverse events was similar between the two groups. Eldecalcitol was more effective than alfacalcidol in maintaining BMD in GIO patients. Because eldecalcitol was effective in patients with no or short-term previous glucocorticoid treatment, as well as those without prevalent fracture or low BMD, eldecalcitol can be a good candidate for primary prevention of GIO. UMI11700.
科研通智能强力驱动
Strongly Powered by AbleSci AI